Altimmune: Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial

 

• Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at Week 48, with weight loss continuing at the end of treatment
• Over 30% of subjects achieved 20% or more weight loss on 2.4 mg dose at 48 weeks
• Robust reductions in BMI and serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate

Altimmune to host conference call tomorrow at 8:30 am EST

Altimmune management will host a conference call and webcast with a slide presentation presented by Dr. Scott Harris, Chief Medical Officer beginning at 8:30 am E.T. tomorrow. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Conference Call Details:
Date:	Friday, December 1
Time:	8:30 am Eastern Time
Webcast:	To listen, the conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Dial-in:	To participate or dial-in, register here to receive the dial-in numbers and unique PIN to access the call.

https://www.globenewswire.com/news-release/2023/11/30/2788970/0/en/Altimmune-Announces-Positive-Topline-Results-from-MOMENTUM-48-Week-Phase-2-Obesity-Trial-of-Pemvidutide.html